Bayer's Gadoquatrane Shows Promise in Pediatric Trial

By Mauro Orru

Bayer said a contrast agent known as gadoquatrane that enhances the visibility of internal body structures in magnetic resonance imaging showed promise in a pediatric study.

The German pharmaceutical and agricultural conglomerate said the study evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging. The company said the study met primary and secondary endpoints.

Bayer said it had already submitted applications for marketing authorization of the substance in markets including Japan, the U.S., the European Union and China, with more to follow in the coming months.

Write to Mauro Orru at [e-mail]

(END) Dow Jones Newswires

12-03-25 1039ET